Search results for "Heart Failure"

showing 10 items of 863 documents

Recombinant growth hormone therapy in patients with ischemic cardiomyopathy : effects on hemodynamics, left ventricular function, and cardiopulmonary…

1999

Background —We studied the effects of recombinant growth hormone (rhGH) on exercise capacity and cardiac function in patients with ischemic cardiomyopathy. Methods and Results —Seven patients (aged 55±9 years) with mild to moderate congestive heart failure (ejection fraction 31±4%) who were on standard therapy were included. The patients were studied at baseline, after 3 months of rhGH treatment, and 3 months after rhGH discontinuation. Cardiac function was assessed by exercise capacity, right heart catheterization at rest and after submaximal exercise, MRI, echocardiography, and Holter monitoring. When administered at a dose of 2 IU/d, rhGH doubled the serum concentration of insulin-like …

Cardiac function curveMalemedicine.medical_specialtyCardiac outputCardiomyopathyMyocardial IschemiaHemodynamicsVentricular Function LeftPhysiology (medical)Internal medicinemedicineHumansVentricular remodelingIschemic cardiomyopathyEjection fractionExercise Tolerancebusiness.industryHuman Growth HormoneHemodynamicsMiddle Agedmedicine.diseaseCombined Modality TherapySurgeryHeart failureCardiologyCardiology and Cardiovascular MedicinebusinessCirculation
researchProduct

Effects of sauna bath on heart failure : A systematic review and meta-analysis

2018

Background: Sauna bath has potential as a lifestyle treatment modality for heart failure (HF). It is important to analyze the current evidence to help suggest paths of future study and potential for clinical application. Hypothesis: Sauna bath has a positive effect on HF patients. Methods: PubMed, Cochrane Library, and CINAHL databases were searched to identify randomized and nonrandomized controlled studies to compare effects of sauna bath with no sauna bath. Studies were searched for both infrared sauna bath and Finnish sauna bath. The strength of evidence was rated using a modified GRADE approach. Out of 1444 studies, nine met the inclusion criteria and were included in this review. Seve…

Cardiac function curveMalemedicine.medical_specialtyInfrared Rayssaunominenheart failureReview030204 cardiovascular system & hematologyCochrane Librarysydämen vajaatoimintaVentricular Function LeftSteam Bath03 medical and health sciences0302 clinical medicineInternal medicineWaon therapyterveysvaikutuksetNatriuretic Peptide BrainmedicineInfrared saunaHumansCardiac and Cardiovascular Systems030212 general & internal medicineAgedHeart FailureEjection fractionKardiologiWaon therapybusiness.industrymeta-analyysiStroke VolumeGeneral Medicinearchitecture.styleRecovery of FunctionMiddle Agedmedicine.diseaseBlood pressureTreatment OutcomearchitectureHeart failureFinnish SaunaCardiologysydän- ja verisuonitauditsauna bathFemaleCardiology and Cardiovascular MedicinebusinessBiomarkers
researchProduct

Local transient myocardial liposomal gene transfer of inducible nitric oxide synthase does not aggravate myocardial function and fibrosis and leads t…

2010

Microcirculation (2010) 17, 69–78. doi: 10.1111/j.1549-8719.2010.00002.x Abstract Background:  This study was designed to explore the effect of transient inducible nitric oxide synthase (iNOS) overexpression via cationic liposome-mediated gene transfer on cardiac function, fibrosis, and microvascular perfusion in a porcine model of chronic ischemia. Methods and Results:  Chronic myocardial ischemia was induced using a minimally invasive model in 23 landrace pigs. Upon demonstration of heart failure, 10 animals were treated with liposome-mediated iNOS-gene-transfer by local intramyocardial injection and 13 animals received a sham procedure to serve as control. The efficacy of this iNOS-gene-…

Cardiac function curveMalemedicine.medical_specialtyPhysiologySus scrofaIschemiaMyocardial IschemiaGene ExpressionNitric Oxide Synthase Type IINitric OxideVentricular Function LeftNeovascularizationFibrosisPhysiology (medical)Internal medicinemedicineAnimalsHumansMolecular BiologyEjection fractionbiologyNeovascularization Pathologicbusiness.industryMyocardiumGene Transfer Techniquesmedicine.diseaseFibrosisMagnetic Resonance ImagingRecombinant ProteinsNitric oxide synthaseArteriolesHeart failureLiposomesCardiologybiology.proteinDobutamineFemalemedicine.symptomCardiology and Cardiovascular Medicinebusinessmedicine.drugMicrocirculation (New York, N.Y. : 1994)
researchProduct

Doxorubicin induces wide-spread transcriptional changes in the myocardium of hearts distinguishing between mice with preserved and impaired cardiac f…

2021

Abstract Aims Doxorubicin (DOX) is an important drug for the treatment of various tumor entities. However, the occurrence of heart failure limits its application. This study investigated differential gene expression profiles in the left and right ventricles of DOX treated mice with either preserved or impaired myocardial function. We provide new mechanistic insights into the pathophysiology of DOX-induced heart failure and have discovered pathways that counteract DOX-induced cardiotoxicity. Main methods We used in total 48 male mice and applied a chronic low dose DOX administration (5 mg/kg per injection, in total 20 mg/kg over 4 weeks) to induce heart failure. Echocardiographic parameters …

Cardiac function curveTranscription GeneticPharmacologymedicine.disease_causeGeneral Biochemistry Genetics and Molecular BiologyElectrocardiographypolycyclic compoundsmedicineAnimalsCluster AnalysisDoxorubicinGeneral Pharmacology Toxicology and Pharmaceuticschemistry.chemical_classificationReactive oxygen speciesCardiotoxicitybusiness.industryGene Expression ProfilingMyocardiumGeneral Medicinemedicine.diseasePathophysiologyMice Inbred C57BLGene expression profilingOxidative StresschemistryDoxorubicinHeart failureHeart Function TestsbusinessOxidative stressmedicine.drugLife Sciences
researchProduct

Procollagen C-Proteinase Enhancer 1 (PCPE-1) is a marker of myocardial fibrosis and impaired cardiac function in a murine model of pressure overload

2021

Abstract(1)AimsProcollagen C-proteinase enhancer 1 (PCPE-1) is an extracellular matrix protein and a major regulator of fibrillar collagen biosynthesis. Previous work has shown that its abundance is often increased in the context of tissue repair and fibrosis. The present study was designed to evaluate its potential as a biomarker of myocardial interstitial fibrosis (MIF), a well-established pathogenic pathway leading to heart failure.(2)Methods and ResultsCardiac fibrosis was induced in rats using an optimized model of chronic pressure overload triggered by angiotensin II and Nω-nitro-L-arginine methyl ester (L-NAME). All treated animals suffered from heart hypertrophy and the increase in …

Cardiac function curvemedicine.medical_specialtyCardiac fibrosis[SDV]Life Sciences [q-bio]Diastoleheart failure030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineFibrosisInternal medicinemedicine030304 developmental biologyPressure overload0303 health sciencesCardiac fibrosiscirculating biomarkerbusiness.industrycollagen biosynthesismedicine.diseaseProcollagen C-proteinase enhancer 1 (PCPE-1)Angiotensin IIEndocrinologyHeart failureMyocardial fibrosisPET-MR imagingbusiness
researchProduct

Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure

2008

AIMS: Recent studies have demonstrated the importance of chromatin remodelling via histone acetylation/deacetylation for the control of cardiac gene expression. Specific histone deacetylases (HDACs) can, in fact, play a positive or negative role in determining cardiac myocyte (CM) size. Here, we report on the effect on hypertrophy development of three inhibitors (HDACi) of class I HDACs. METHODS AND RESULTS: The compounds were first analysed in vitro by scoring hypertrophy, expression of foetal genes, and apoptosis of neonatal rat CMs stimulated with phenylephrine, an alpha1-adrenergic agonist. This initial screening indicated that a truncated derivative of apicidin with class I HDAC specif…

Cardiac function curvemedicine.medical_specialtyHypertrophy Heart failurePhysiologymedicine.drug_classBiologyPeptides CyclicHistone DeacetylasesCell LineMuscle hypertrophychemistry.chemical_compoundPhysiology (medical)Internal medicinemedicineAnimalsHumansMyocytes CardiacEnzyme InhibitorsRats WistarCells CulturedHeart FailurePressure overloadHistone deacetylase inhibitorHypertrophic cardiomyopathyHypertrophymedicine.diseaseRatsHistone Deacetylase InhibitorsDisease Models AnimalEndocrinologychemistryEchocardiographyHeart failureHypertrophy Left VentricularHistone deacetylaseCardiology and Cardiovascular MedicineApicidinCardiovascular Research
researchProduct

2021

AIMS Platelet indices have been associated with traditional cardiovascular risk factors, cardiovascular diseases and all-cause mortality. This study aimed to investigate the role of platelet count, mean platelet volume (MPV) and platelet-to-leukocyte ratio, including platelet-to-monocyte and platelet-to-lymphocyte ratio with cardiac function, heart failure (HF) phenotypes and clinical outcome, worsening of HF. METHODS AND RESULTS Univariate and multivariable linear and Cox regression analyses were used to investigate the associations between platelet indices, cardiac function and worsening of HF in 3250 subjects enrolled in the MyoVasc study. Higher MPV, lower platelet count, lower platelet…

Cardiac function curvemedicine.medical_specialtyPercentileEjection fractionbusiness.industryProportional hazards modelConfoundingHazard ratio030204 cardiovascular system & hematologymedicine.disease03 medical and health sciences0302 clinical medicineInternal medicineHeart failuremedicineCardiology030212 general & internal medicineMean platelet volumeCardiology and Cardiovascular MedicinebusinessESC Heart Failure
researchProduct

Hämodynamik nach sublingualer Applikation von Captopril bei schwerer Herzinsuffizienz*: Eine Pilotstudie

2008

In a preliminary trial, 23 patients in severe left-heart failure and, in some instances, also right-heart failure (NYHA classes III and IV) received a single sublingual dose of 25 mg captopril. Invasive measurement of various haemodynamic parameters indicated (1) an increase in cardiac index and stroke-volume index of 34% and 38%, respectively (P less than 0.001 for each); (2) decrease in pulmonary artery and systemic pressures by an average of 7% and 11.4% (P less than 0.01 and less than 0.001, respectively); (3) no significant change in heart rate and mean right atrial pressure; (4) decrease in systemic and pulmonary artery resistance by 33% and 29% (P less than 0.001 for both); (5) an in…

Cardiac function curvemedicine.medical_specialtybusiness.industryCardiac indexHemodynamicsCaptoprilGeneral Medicinemedicine.diseaseSublingual administrationHeart failureInternal medicinemedicine.arteryHeart ratePulmonary arterymedicineCardiologybusinessmedicine.drugDMW - Deutsche Medizinische Wochenschrift
researchProduct

Abstract 13812: Pulmonary Function Predicts Cardiac Function, Structure & Clinical Outcome in Chronic Heart Failure: Results From the Myovasc Stu…

2020

Introduction: A growing body of evidence suggests a relevance of pulmonary function in the pathophysiology of heart failure (HF). Comprehensive data on the role of forced expiratory volume in 1 second (FEV1) in the development & progression of HF is limited. Hypothesis: Given this background, we hypothesized, that (FEV1) is associated with deteriorated left ventricular (LV) functional as well as structural status, & predicts specific clinical outcome in HF. Methods: Data from the MyoVasc Study (n=3,289) were analysed. Comprehensive clinical phenotyping including body plethysmography for the evaluation of FEV1 & standardized echocardiography were performed during a five-hour inv…

Cardiac function curvemedicine.medical_specialtybusiness.industrymedicine.diseaseOutcome (game theory)PathophysiologyPulmonary function testingPhysiology (medical)Internal medicineHeart failureEpidemiologyCardiologymedicineCardiology and Cardiovascular MedicinebusinessCirculation
researchProduct

Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive r…

2011

Background— Diastolic dysfunction associated with high blood pressure (BP) leads to cardiac remodeling and fibrosis and progression to congestive heart failure. B-type natriuretic peptide (BNP) has BP-lowering, antifibrotic, and antihypertrophic properties, which makes BNP an attractive agent for attenuating the adverse cardiac remodeling associated with hypertension. In the current study, we tested the effects of sustained cardiac proBNP gene delivery on BP, cardiac function, and remodeling in spontaneously hypertensive rats (SHR). Methods and Results— We used the myocardium-tropic adeno-associated virus serotype 9 (AAV9) vector to achieve continuously enhanced cardiac rat proBNP expressi…

Cardiac function curvemedicine.medical_specialtymedicine.drug_classBNP; Natyriuretic peptides; hypertensive heart diseaseDiastolePhysiology (medical)Internal medicinemedicineNatriuretic peptideNatyriuretic peptidescardiovascular diseasesVentricular remodelingEjection fractionbusiness.industryheart failure natriuretic peptide hypertension.medicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareHypertensive heart diseaseBlood pressureEndocrinologyHeart failurecardiovascular systemCardiologyCardiology and Cardiovascular Medicinebusinesshypertensive heart diseasehormones hormone substitutes and hormone antagonistsBNP
researchProduct